Phase I Study: MTI-301 in Advanced/Metastatic/Refractory Solid Tumors

Mayo Clinic is assessing MTI-301—a first-in-human SCD1 inhibitor—as monotherapy in patients with unresectable or metastatic solid tumors with no standard care options. Participants receive MTI-301 orally once daily on days 1–28 of each 28‐day cycle, with imaging and biospecimen collection to evaluate safety, tolerability, and preliminary activity.